RESUMEN
Background: Managing patients with cancer during the coronavirus disease 2019 (COVID-19) pandemic has been challenging. Disruptions in cancer management have been observed due to cancellation of treatment, issues related to commuting, and dearth of health-care workers. Objective(s): This study was conducted during the first wave of the COVID-19 pandemic and was aimed at evaluating the 30-day all-cause mortality among patients with cancer and COVID-19 infection and the factors affecting it. Material(s) and Method(s): In this retrospective study, we collected secondary data from nine tertiary care centers in South India over a period of 10 months from March to Dec 2020. Patients across all age groups with histopathologically confirmed diagnosis of cancer who were affected by COVID-19 during their evaluation or treatment were included in the study. The primary outcome variables of the present study were 30-day all-cause mortality, cancer outcomes, and COVID-19 outcomes. Result(s): A total of 206 patients were included. Median age of the cohort was 55.5 years, and the male-To-female ratio was 1:1.03. The 30-day mortality rate was 12.6%. Twenty-Two patients (10.7%) had severe COVID-19 infection at the initial presentation. Predictors for severe pneumonia at the initial presentation were incomplete remission at the time of COVID-19 diagnosis and palliative intent of treatment. Severe pneumonia at the initial presentation, diagnosis of COVID-19 on or before August 2020, and need for ventilator support were associated with increased mortality. Conclusion(s): Severity of infection at the initial presentation, cancer status, and the intent of cancer treatment impact COVID-19 outcomes in patients with cancer.Copyright © 2022 Iranian Society of Ophthalmology. All rights reserved.
RESUMEN
The severe acute respiratory syndrome produced by COVID-19 is a highly infectious and pathogenic viral infection. Many COVID-19 patients have secondary bacterial infections, which enhance disease and increase death, particularly when requiring invasive mechanical ventilation. One of the most important medicinal mushrooms, Ganoderma lucidum, has been used for food, feed, and medication since the dawn of humanity. The present investigation aims to discover the potential of the medicinal mushroom Ganoderma lucidum inhibited multidrug-resistant isolates from secondary infection of Covid-19 patients. Isolation and identification of urine samples from secondary infection of post-Covid-19 patients and evaluate the antibiotic sensitivity assay, as identification of bioactive compounds, anti-inflammatory and antioxidant activity from Ganoderma lucidum. Totally 6 clinical urine samples were collected from the age group 45 to 60;3 were male, and 3 were female. In total, nine bacteria and 10 fungi were isolated and identified. As antibiotic sensitivity assays of ceftriaxone, fluoroquinolones, azithromycin and amphotericin, nystatin and fluconazole were performed by the disc diffusion method against bacteria and fungi, the zone of inhibition was maximal in Klebsiella pneumoniae and Fusarium oxysporum. The aqueous and ethanolic extracts of Ganoderma lucidum were analyzed for the bioactive compounds, viz., steroids, flavonoids, alkaloids and phenolic compounds. The effect of the anti-inflammatory activity of the aqueous extract was excellent. The activity of the DPPH assay was maximum in aqueous and ethanolic extracts of all concentrations (100 to 500 ml). Antibiotic resistance could probably rise due to the frequent prescription of broad-spectrum empiric antimicrobials to COVID-19 patients. Hence, Ganoderma lucidum can be exploited to prevent secondary infection in COVID-19 patients.